Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 30;15(7):2056.
doi: 10.3390/cancers15072056.

Combination of FDG PET/CT Radiomics and Clinical Parameters for Outcome Prediction in Patients with Hodgkin's Lymphoma

Claudia Ortega  1 , Yael Eshet  2 , Anca Prica  3 , Reut Anconina  4 , Sarah Johnson  1 , Danny Constantini  5 , Sareh Keshavarzi  6 , Roshini Kulanthaivelu  1 , Ur Metser  1 , Patrick Veit-Haibach  1
Affiliations

Combination of FDG PET/CT Radiomics and Clinical Parameters for Outcome Prediction in Patients with Hodgkin's Lymphoma

Claudia Ortega et al. Cancers (Basel). .

Abstract

Purpose: The aim of the study is to evaluate the prognostic value of a joint evaluation of PET and CT radiomics combined with standard clinical parameters in patients with HL.

Methods: Overall, 88 patients (42 female and 46 male) with a median age of 43.3 (range 21-85 years) were included. Textural analysis of the PET/CT images was performed using freely available software (LIFE X). 65 radiomic features (RF) were evaluated. Univariate and multivariate models were used to determine the value of clinical characteristics and FDG PET/CT radiomics in outcome prediction. In addition, a binary logistic regression model was used to determine potential predictors for radiotherapy treatment and odds ratios (OR), with 95% confidence intervals (CI) reported. Features relevant to survival outcomes were assessed using Cox proportional hazards to calculate hazard ratios with 95% CI.

Results: albumin (p = 0.034) + ALP (p = 0.028) + CT radiomic feature GLRLM GLNU mean (p = 0.012) (Area under the curve (AUC): 95% CI (86.9; 100.0)-Brier score: 3.9, 95% CI (0.1; 7.8) remained significant independent predictors for PFS outcome. PET-SHAPE Sphericity (p = 0.033); CT grey-level zone length matrix with high gray-level zone emphasis (GLZLM SZHGE mean (p = 0.028)); PARAMS XSpatial Resampling (p = 0.0091) as well as hemoglobin results (p = 0.016) remained as independent factors in the final model for a binary outcome as predictors of the need for radiotherapy (AUC = 0.79).

Conclusion: We evaluated the value of baseline clinical parameters as well as combined PET and CT radiomics in HL patients for survival and the prediction of the need for radiotherapy treatment. We found that different combinations of all three factors/features were independently predictive of the here evaluated endpoints.

Keywords: PET/CT; hodgkin lymphoma; predictor models; radiomics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PET contouring using LifeX software of an 18-year-old male patient with Stage I Hodgkin Lymphoma.
Figure 2
Figure 2
Calibration plots and AUC considering different variables in the model.
Figure 3
Figure 3
AUC for the final Radiotherapy model provided below.
Figure 4
Figure 4
Forrest plot for MVA model correlating with PFS.
Figure 5
Figure 5
Forrest plot for MVA model when correlating with radiotherapy outcome.
See this image and copyright information in PMC

References

    1. Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer Statistics, 2021. CA A Cancer J. Clin. 2021;71:7–33. doi: 10.3322/caac.21654. - DOI - PubMed
    1. Engert A., Plütschow A., Eich H.T., Lohri A., Dörken B., Borchmann P., Berger B., Greil R., Willborn K.C., Wilhelm M., et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N. Engl. J. Med. 2010;363:640–652. doi: 10.1056/NEJMoa1000067. - DOI - PubMed
    1. Eich H.T., Diehl V., Görgen H., Pabst T., Markova J., Debus J., Ho A., Dörken B., Rank A., Grosu A.-L., et al. Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin’s Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial. J. Clin. Oncol. 2010;28:4199–4206. doi: 10.1200/JCO.2010.29.8018. - DOI - PubMed
    1. Bonfante V., Santoro A., Viviani S., Devizzi L., Balzarotti M., Soncini F., Zanini M., Valagussa P., Bonadonna G. Outcome of patients with Hodgkin’s disease failing after primary MOPP-ABVD. J. Clin. Oncol. 1997;15:528–534. doi: 10.1200/JCO.1997.15.2.528. - DOI - PubMed
    1. Moskowitz C.H., KewalRamani T., Nimer S.D., Gonzalez M., Zelenetz A., Yahalom J. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin’s disease. Br. J. Haematol. 2004;124:645–652. doi: 10.1111/j.1365-2141.2003.04828.x. - DOI - PubMed

LinkOut - more resources